Qualitest, one of the world’s leading AI-powered, engineering-driven software testing and quality assurance companies, has announced the acquisition of Israel-based Comply, a quality assurance specialist in Pharma and Digital Health.
The deal will add 83 of Comply’s employees into the Qualitest team and will add Teva, Merck, Johnson & Johnson, GE Medical and AbbVie to Qualitest’s list of high-profile clients. Following the acquisition, Teva will become one of Qualitest’s leading pharmaceutical accounts globally.
As a strategic partner, Qualitest helps brands move beyond functional testing to adopt new innovations such as automation, AI and crowd sourced UX testing. It leverages its domain expertise across industries, including insurance and financial services, media and entertainment, retail, consumer goods, technology, gaming, telecom, aerospace, among others.
Norm Merritt, CEO, Qualitest, said, “We’ve had our eyes on Comply for a while due to its reputation as a leader in providing software testing services to the growing pharma tech market. That’s why we are excited to bring them into the Qualitest family. We see a lot of potential in the pharma industry, and by integrating Comply’s expertise we can expand Qualitest’s footprint in this hot-growth area.”
Gai Anbar, Founder and CEO, Comply, said, “Qualitest is a global leader in testing, which is why it’s the perfect partner to help us take our testing services worldwide. We have been impressed with Qualitest’s position as the go-to provider for software testing. By joining forces, we can capitalize on our own expertise in providing the highest quality assurance for health and pharma businesses.”
